Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease.

This study impacts the RA and ILD fields by helping to identify a therapeutic treatment that may improve both diseases. As this model replicates the characteristics of RA-ILD, the results may be translatable to the human disease.
PMID: 29543042 [PubMed - as supplied by publisher]

Source: American Journal of Physiology. Lung Cellular and Molecular Physiology - March 15, 2018 Category: Cytology Authors: Redente EF, Aguilar MA, Black BP, Edelman B, Bahadur A, Humphries SM, Lynch DA, Wollin L, Riches DWH Tags: Am J Physiol Lung Cell Mol Physiol Source Type: research